Gillett, M. (Michael), Royle, Pamela, Snaith, Ailsa, Scotland, Graham, Poobalan, A. S., Imamura, M. (Mari), Black, C. (Corrinda), Boroujerdi, M., Jick, S., Wyness, L., McNamee, Paul, Brennan, Alan and Waugh, Norman. (2012) Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation : a systematic review and economic evaluation. Health Technology Assessment, Vol.16 (No.33). ISSN 1366-5278

Preview	Text WRAP_Waugh_Non-pharmacological_prevention TAR.pdf - Published Version Download (1569Kb) | Preview
Preview	Text (Cover sheet) WRAP_waugh_Coversheet_FinalVersion.pdf - Other Download (203Kb) | Preview

Abstract

Background The prevalence of type 2 diabetes mellitus (T2DM) is increasing in the UK and worldwide. Before the onset of T2DM, there are two conditions characterised by blood glucose levels that are above normal but below the threshold for diabetes. If screening for T2DM in introduced, many people with impaired glucose tolerance (IGT) will be found and it is necessary to consider how they should be treated. The number would depend on what screening test was used and what cut-offs were chosen. Objective To review the clinical effectiveness and cost-effectiveness of non-pharmacological interventions, including diet and physical activity, for the prevention of T2DM in people with intermediate hyperglycaemia. Data sources Electronic databases, MEDLINE (1996–2011), EMBASE (1980–2011) and all sections of The Cochrane Library, were searched for systematic reviews, randomised controlled trials (RCTs) and other relevant literature on the effectiveness of diet and/or physical activity in preventing, or delaying, progression to T2DM.The databases were also searched for studies on the cost-effectiveness of interventions. Review methods The review of clinical effectiveness was based mainly on RCTs, which were critically appraised. Subjects were people with intermediate hyperglycaemia, mainly with IGT. Interventions could be diet alone, physical activity alone, or the combination. For cost-effectiveness analysis, we updated the Sheffield economic model of T2DM. Modelling based on RCTs may not reflect what happens in routine care so we created a ‘real-life’ modelling scenario wherein people would try lifestyle change but switch to metformin after 1 year if they failed. Results Nine RCTs compared lifestyle interventions (predominantly dietary and physical activity advice, with regular reinforcement and frequent follow-up) with standard care. The primary outcome was progression to diabetes. In most trials, progression was reduced, by over half in some trials. The best effects were seen in participants who adhered best to the lifestyle changes; a scenario of a trial of lifestyle change but a switch to metformin after 1 year in those who did not adhere sufficiently appeared to be the most cost-effective option. Limitations Participants in the RCTs were volunteers and their results may have been better than in general populations. Even among the volunteers, many did not adhere. Some studies were not long enough to show whether the interventions reduced cardiovascular mortality as well as diabetes. The main problem is that we know what people should do to reduce progression, but not how to persuade most to do it. Conclusion In people with IGT, dietary change to ensure weight loss, coupled with physical activity, is clinically effective and cost-effective in reducing progression to diabetes.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Non-insulin-dependent diabetes -- Prevention, Hyperglycemia -- Treatment, Hyperglycemia -- Diet therapy, Hyperglycemia -- Exercise therapy
Journal or Publication Title:	Health Technology Assessment
Publisher:	NIHR Health Technology Assessment programme
ISSN:	1366-5278
Date:	2012
Volume:	Vol.16
Number:	No.33
Identification Number:	10.3310/hta16330
Status:	Peer Reviewed
Publication Status:	Published
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
References:	1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–53. 2. Moore P. Type 2 diabetes is a major drain on resources. BMJ 2000;320:732. 3. Diabetes UK. Diabetes in the UK 2010: key statistics on diabetes. 2010. URL: www.diabetes. org.uk/Documents/Reports/Diabetes_in_the_UK_2010.pdf (accessed 22 March 2012). 4. Department of Health (DH). Health Profile of England 2009. March 2010. URL: www.dh.gov. uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_114561 (accessed 22 March 2012). 5. Yorkshire & Humber Public Health Observatory. Diabetes key facts. 2006. URL: www.yhpho. org.uk/resource/item.aspx?RID=8872 (accessed 1 February 2012). 6. Yorkshire & Humber Public Health Observatory. APHO Diabetes Prevalence Model. 2011. URL: www.yhpho.org.uk/default.aspx?RID=81090 (accessed 1 February 2012). 7. National Statistics. Health Survey for England 2004: the health of minority ethnic groups. 2005. URL: www.ic.nhs.uk/webfiles/publications/hlthsvyeng2004ethnic/ HealthSurveyForEngland161205_PDF%20.pdf (accessed 22 March 2012). 8. Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health care burden of type 2 diabetes in the UK from 2000 to 2060. Diabet Med 2002;19(Suppl. 4):1–5. 9. Department of Health (DH). National Service Framework for Diabetes. 2001. URL: www. dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ Browsable/DH_4096591 (accessed 22 March 2012). 10. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73–8. 11. Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53. 12. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421–31. 13. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27–38. 14. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187–218. 15. Lebovitz HE. Insulin resistance: a common link between type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 2006;8:237–49. 16. International Diabetes Federation. Diabetes atlas: second edition. 2002 URL: www.idf.org/ sites/default/files/IDF_Diabetes_Atlas_2ndEd.pdf (accessed 22 March 2012). 17. Jarrett RJ. Is there an ideal body weight? Br Med J 1986;293:493–5. 18. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997;146:214–22. 19. National Audit Office. Tackling obesity in England. 2001. URL: www.nao.org.uk/ publications/0001/tackling_obesity_in_England.aspx (accessed 22 March 2012). 20. Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care 2007;30:744–52. 21. Sui X, LaMonte MJ, Laditka JN, Hardin JW, Chase N, Hooker SP, et al. Cardiorespiratory fitness and adiposity as mortality predictors in older adults. JAMA 2007;298:2507–16. 22. Thomas C, Hypponen E, Power C. Diabetes risk in British adults in mid life: a national prevalence study of glycated haemoglobin. Diabet Med 2007;24:317–21. 23. Invitti C, Guzzaloni G, Gilardini L, Morabito F, Viberti G. Prevalence and concomitants of glucose intolerance in European obese children and adolescents. Diabetes Care 2003;26:118–24. 24. Balakrishnan R, Webster P, Sinclair D. Trends in overweight and obesity among 5–7-yearold White and South Asian children born between 1991 and 1999. J Public Health 2008;30:139–44. 25. Ehtisham S, Hattersley AT, Dunger DB, Barrett TG. First UK survey of paediatric type 2 diabetes and MODY. Arch Dis Child 2004;89:526–9. 26. Turner R, Cull C, Holman R. United Kingdom prospective diabetes study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:136–45. 27. UKPDS Study Group. UKPDS 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995;44:1249–58. 28. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711–21. 29. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: newer agents (partial update of CG66). Clinical Guideline CG87. 2009, May. URL: www.nice.org.uk/CG87 (accessed 1 February 2012). 30. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14(36). 31. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999;130:389–96. 32. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997;278:1663–9. 33. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736–42. 34. World Health Organization (WHO). Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006. URL: www.who.int/ diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf (accessed 22 March 2012). 35. Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care 2003;26:2335–40. 36. American Diabetes Association (ADA). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl. 1):5–20. 37. Balkau B, Hillier T, Vierron E, D’Hour A, Lepinay P, Royer B, et al. Comment to: Borch- Johnsen K, Colagiuri S, Balkau B, et al. (2004) Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 47:1396–402. Diabetologia 2005;48:801–2. 38. Agency for Healthcare Research and Quality (AHRQ). Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence Report/Technology Assessment no. 128. 2005. URL: www.ahrq.gov/clinic/tp/impglutp.htm (accessed 22 March 2012). 39. Balkau B, Eschwege E, Tichet J, Marre M. Proposed criteria for the diagnosis of diabetes: evidence from a French epidemiological study (D.E.S.I.R.). Diabetes Metab 1997;23:428–34. 40. Forouhi NG, Luan J, Hennings S, Wareham NJ. Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990–2000. Diabet Med 2007;24:200–7. 41. Qiao Q, Lindström J, Valle TT, Tuomilehto J. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet Med 2003;20:1027–33. 42. Rasmussen SS, Glumer C, Sandbaek A, Lauritzen T, Borch-Johnsen K. Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION Study, Denmark. Diabetologia 2007;50:293–7. 43. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 2007;30:228–33. 44. Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962–1972): glucose tolerance and diabetes. Diabetologia 1982;22:73–8. 45. Little RR, England JD, Wiedmeyer HM, Madsen RW, Pettitt DJ, Knowler WC, et al. Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance. Diabetologia 1994;37:252–6. 46. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997;46:701–10. 47. Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2006;29:1619–25. 48. Yoshinaga H, Kosaka K. High glycosylated hemoglobin levels increase the risk of progression to diabetes mellitus in subjects with glucose intolerance. Diabetes Res Clin Pract 1996;31:71–9. 49. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–93. 50. Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299:316–23. 51. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617–21. 52. Pan XR, Hu YH, Li GW, Liu PA, Bennett PH, Howard BV. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study. Diabetes Care 1993;16:150–6. 53. Rewers M, Shetterly SM, Baxter J, Marshall JA, Hamman RF. Prevalence of coronary heart disease in subjects with normal and impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a biethnic Colorado population. The San Luis Valley Diabetes Study. Am J Epidemiol 1992;135:1321–30. 54. Jarrett RJ. The cardiovascular risk associated with impaired glucose tolerance. Diabet Med 1996;13:S15–19. 55. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920–4. 56. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:151–7. 57. Davies MJ, Muehlbayer S, Garrick P, McNally PG. Potential impact of a change in the diagnostic criteria for diabetes mellitus on the prevalence of abnormal glucose tolerance in a local community at risk of diabetes: impact of new diagnostic criteria for diabetes mellitus. Diabet Med 1999;16:343–6. 58. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991;337:382–6. 59. Forrest RD, Jackson CA, Yudkin JS. Glucose intolerance and hypertension in north London: the Islington Diabetes Survey. Diabet Med 1986;3:338–42. 60. Phillips DI, Goulden P, Syddall HE, Aihie SA, Dennison EM, Martin H, et al. Fetal and infant growth and glucose tolerance in the Hertfordshire Cohort Study: a study of men and women born between 1931 and 1939. Diabetes 2005;54(Suppl. 2):145–50. 61. Thomas MC, Walker MK, Emberson JR, Thomson AG, Lawlor DA, Ebrahim S, et al. Prevalence of undiagnosed type 2 diabetes and impaired fasting glucose in older British men and women. Diabet Med 2005;22:789–93. 62. Simmons D, Williams DR, Powell MJ. The Coventry Diabetes Study: prevalence of diabetes and impaired glucose tolerance in Europids and Asians. Q J Med 1991;81:1021–30. 63. Dunstan DW, Zimmet PZ, Welborn TA, De Court, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002;25:829–34. 64. Glatthaar C, Welborn TA, Stenhouse NS, Garcia-Webb P. Diabetes and impaired glucose tolerance. A prevalence estimate based on the Busselton 1981 survey. Med J Aust 1985;143:436–40. 65. Guest CS, O’Dea K, Hopper JL, Nankervis AJ, Larkins RG. The prevalence of glucose intolerance in aborigines and Europids of south-eastern Australia. Diabetes Res Clin Pract 1992;15:227–35. 66. Unwin N, Harland J, White M, Bhopal R, Winocour P, Stephenson P, et al. Body mass index, waist circumference, waist–hip ratio, and glucose intolerance in Chinese and Europid adults in Newcastle, UK. J Epidemiol Community Health 1997;51:160–6. 67. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993;16:157–77. 68. Tapp RJ, Dunstan DW, Phillips P, Tonkin A, Zimmet PZ, Shaw JE. Association between impaired glucose metabolism and quality of life: results from the Australian diabetes obesity and lifestyle study. Diabetes Res Clin Pract 2006;74:154–61. 69. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, doubleblind trial. JAMA 1998;280:1490–6. 70. Testa MA, Simonson DC, Turner RR. Valuing quality of life and improvements in glycemic control in people with type 2 diabetes. Diabetes Care 1998;21:C44–52. 71. Waugh N, Millard A, Robertson L, Royle P. Research review for the Scottish Public Health Network. Screening for and prevention of type 2 diabetes. 2011. URL: www.scotphn.net/ projects/previous_projects/type_2_diabetes_needs_assessment (accessed 22 March 2012). 72. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007;11(17). 73. UK National Screening Committee (NSC). The UK NSC policy on Diabetes screening in adults. 2012. URL: www.screening.nhs.uk/diabetes (accessed 22 March 2012). 74. Holbrook TL, Barrett-Connor E, Wingard DL. The association of lifetime weight and weight control patterns with diabetes among men and women in an adult community. Int J Obes 1989;13:723–9. 75. Manson JE, Spelsberg A. Primary prevention of non-insulin-dependent diabetes mellitus. Am Prev Med 1994;10:172–84. 76. Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990;132:501–13. 77. Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. Am J Clin Nutr 2006;84:483–9. 78. Zaninotto P, Mindell J, Hirani V. Prevalence of cardiovascular risk factors among ethnic groups: results from the Health Surveys for England. Atherosclerosis 2007;195:e48–57. 79. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481–6. 80. Hart CL, Hole DJ, Lawlor DA, Davey SG. How many cases of type 2 diabetes mellitus are due to being overweight in middle age? Evidence from the Midspan prospective cohort studies using mention of diabetes mellitus on hospital discharge or death records. Diabet Med 2007;24:73–80. 81. Jiang Y, Chen Y, Mao Y. The contribution of excess weight to prevalent diabetes in Canadian adults. Public Health 2008;122:271–6. 82. Han TS, Sattar N, Lean M. ABC of obesity. Assessment of obesity and its clinical implications. BMJ 2006;333:695–8. 83. Diabetes Prevention Program Research Group. Relationship of body size and shape to the development of diabetes in the diabetes prevention program. Obesity 2006;14:2107–17. 84. Diaz VA, Mainous AG, Baker R, Carnemolla M, Majeed A. How does ethnicity affect the association between obesity and diabetes? Diabet Med 2007;24:1199–204. 85. Hu FB, van Dam RM, Liu S. Diet and risk of Type II diabetes: the role of types of fat and carbohydrate. Diabetologia 2001;44:805–17. 86. American Diabetes Association. Nutrition Recommendations and Interventions for Diabetes: a position statement of the American Diabetes Association. Diabetes Care 2007;30(Suppl. 1):48–65. 87. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002;25:148–98. 88. Riccardi G, Rivellese AA, Giacco R. Role of glycemic index and glycemic load in the healthy state, in prediabetes, and in diabetes. Am J Clin Nutr 2008;87:S269–74. 89. Carter P, Gray LJ, Troughton J, Khunti K, Davies MJ. Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis. BMJ 2010;341:c4229. 90. Hays NP, Galassetti PR, Coker RH. Prevention and treatment of type 2 diabetes: Current role of lifestyle, natural product, and pharmacological interventions. Pharmacol Ther 2008;118:181–91. 91. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS, Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991;325:147–52. 92. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991;34:891–8. 93. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, et al. Prevention or delay of type 2 diabetes. Diabetes Care 2004;27(Suppl. 1):47–54. 94. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C. Physical activity/exercise and type 2 diabetes. Diabetes Care 2004;27:2518–39. 95. Diabetes Australia. Evidence based guideline for the primary prevention of type 2 diabetes. 2008. URL: www.diabetesaustralia.com.au/PageFiles/763/Primarypreventionguideline.pdf (accessed 22 March 2012). 96. Wallberg-Henriksson H, Rincon J, Zierath JR. Exercise in the management of non-insulindependent diabetes mellitus. Sports Med 1998;25:25–35. 97. Burchfiel CM. Physical activity and incidence of diabetes: The Honolulu Heart Program. Am J Epidemiol 1995;141:360–8. 98. Manson JE, Nathan DM, Krolewski AS, Stampfer MJ, Willett WC, Hennekens CH. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 1992;268:63–7. 99. Manson JE, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, Krolewski AS, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991;338:774–8. 100. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;3:CD002968. 101. Hu FB, Sigal RJ, Rich-Edwards JW, Colditz GA, Solomon CG, Willett WC, et al. Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA 1999;282:1433–9. 102. Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005;99:1193–204. 103. Mayer-Davis EJ, D’Antonio A, Martin M, Wandersman A, Parra-Medina D, Schulz R. Pilot study of strategies for effective weight management in type 2 diabetes: Pounds Off with Empowerment (POWER). Fam Community Health 2001;24:27–35. 104. Kriska A. Physical activity and the prevention of type 2 diabetes mellitus: how much for how long? Sports Med 2000;29:147–51. 105. Haapanen N, Miilunpalo S, Pasanen M, Oja P, Vuori I. Association between leisure time physical activity and 10-year body mass change among working-aged men and women. Int J Obes Relat Metab Disord 1997;21:288–96. 106. Perry IJ, Wannamethee SG, Walker MK, Thomson AG, Whincup PH, Shaper AG. Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ 1995;310:560–4. 107. Wannamethee SG, Shaper AG, Walker M, Ebrahim S. Lifestyle and 15-year survival free of heart attack, stroke, and diabetes in middle-aged British men. Arch Intern Med 1998;158:2433–40. 108. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403. 109. Eriksen L, Dahl-Petersen I, Haugaard SB, Dela F. Comparison of the effect of multiple short-duration with single long-duration exercise sessions on glucose homeostasis in type 2 diabetes mellitus. Diabetologia 2007;50:2245–53. 110. Eves ND, Plotnikoff RC. Resistance training and type 2 diabetes: considerations for implementation at the population level. Diabetes Care 2006;29:1933–41. 111. Zachwieja JJ, Toffolo G, Cobelli C, Bier DM, Yarasheski KE. Resistance exercise and growth hormone administration in older men: effects on insulin sensitivity and secretion during a stable-label intravenous glucose tolerance test. Metabolism 1996;45:254–60. 112. Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Metz-Schimmerl S, Pacini G, et al. The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus. Arch Phys Med Rehabil 2005;86:1527–33. 113. Castaneda C, Layne JE, Munoz-Orians L, Gordon PL, Walsmith J, Foldvari M, et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 2002;25:2335–41. 114. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 2006;29:2518–27. 115. Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud’homme D, Fortier M, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007;147:357–69. 116. Gill JM, Cooper AR. Physical activity and prevention of type 2 diabetes mellitus. Sports Med 2008;38:807–24. 117. Eriksson JG. Exercise and the treatment of type 2 diabetes mellitus. An update. Sports Med 1999;27:381–91. 118. Schneider SH, Khachadurian AK, Amorosa LF, Clemow L, Ruderman NB. Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care 1992;15:1800–10. 119. King AC, Haskell WL, Young DR, Oka RK, Stefanick ML. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 1995;91:2596–604. 120. Perri MG, Anton SD, Durning PE, Ketterson TU, Sydeman SJ, Berlant NE, et al. Adherence to exercise prescriptions: effects of prescribing moderate versus higher levels of intensity and frequency. Health Psychol 2002;21:452–8. 121. Dishman RK, Buckworth J. Increasing physical activity: a quantitative synthesis. Med Sci Sports Exerc 1996;28:706–19. 122. McGinnis JM. Diabetes and physical activity: Translating evidence into action. Am J Prev Med 2002;22:1–2. 123. Pereira MA, Kriska AM, Day RD, Cauley JA, LaPorte RE, Kuller LH. A randomized walking trial in postmenopausal women: effects on physical activity and health 10 years later. Arch Intern Med 1998;158:1695–701. 124. National Center for Chronic Disease Prevention and Health Promotion. Physical activity and health: a report of the surgeon general. 1999. URL: www.cdc.gov/nccdphp/sgr/sgr.htm (accessed 22 March 2012). 125. Jakicic JM, Wing RR, Butler BA, Robertson RJ. Prescribing exercise in multiple short bouts versus one continuous bout: effects on adherence, cardiorespiratory fitness, and weight loss in overweight women. Int J Obes Relat Metab Disord 1995;19:893–901. 126. Avenell A, Sattar N, Lean M. ABC of obesity. Management: Part I – behaviour change, diet, and activity. BMJ 2006;333:740–3. 127. Sallis JF, Haskell WL, Fortmann SP, Vranizan KM, Taylor CB, Solomon DS. Predictors of adoption and maintenance of physical activity in a community sample. Prev Med 1986;15:331–41. 128. Pollock ML, Carroll JF, Graves JE, Leggett SH, Braith RW, Limacher M, et al. Injuries and adherence to walk/jog and resistance training programs in the elderly. Med Sci Sports Exerc 1991;23:1194–200. 129. Iverson DC, Fielding JE, Crow RS, Christenson GM. The promotion of physical activity in the United States population: the status of programs in medical, worksite, community, and school settings. Public Health Rep 1985;100:212–24. 130. Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004;351:2694–703. 131. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Physical activity/ exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006;29:1433–8. 132. Hillsdon M, Foster C, Cavill N, Crombie H, Naidoo B. Health Development Agency. Effectiveness of public health interventions for increasing physical activity among adults: a review of reviews (evidence briefing). 2nd edn. 2005. URL: www.nice.org.uk/niceMedia/pdf/ physical_activity_adults_eb.pdf (accessed 22 March 2012). 133. Di LC, Fanelli C, Lucidi P, Murdolo G, De CA, Parlanti N, et al. Validation of a counseling strategy to promote the adoption and the maintenance of physical activity by type 2 diabetic subjects. Diabetes Care 2003;26:404–8. 134. Ogilvie D, Foster CE, Rothnie H, Cavill N, Hamilton V, Fitzsimons CF, et al. Interventions to promote walking: systematic review. BMJ 2007;334:1204. 135. Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health 2004;58:441–5. 136. Cappuccio FP, Cook DG, Atkinson RW, Strazzullo P. Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London. Heart 1997;78:555–63. 137. McKeigue PM, Pierpoint T, Ferrie JE, Marmot MG. Relationship of glucose intolerance and hyperinsulinaemia to body fat pattern in south Asians and Europeans. Diabetologia 1992;35:785–91. 138. Barnett AH, Dixon AN, Bellary S, Hanif MW, O’hare JP, Raymond NT, et al. Type 2 diabetes and cardiovascular risk in the UK south Asian community. Diabetologia 2006;49:2234–46. 139. Gulliford MC, Mejia A. Trends in diabetes mellitus in Greater London 1991–2011: associations with ethnicity. Diabet Med 1999;16:174–5. 140. Davies MJ, Ammari F, Sheriff C, Burden ML, Gujral J, Burden AC. Screening for type 2 diabetes mellitus in the UK Indo-Asian population. Diabet Med 1999;16:131–7. 141. Mather HM, Keen H. The Southall Diabetes Survey: prevalence of known diabetes in Asians and Europeans. Br Med J 1985;291:1081–4. 142. Riste L, Khan F, Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care 2001;24:1377–83. 143. Chowdhury TA, Hitman GA. Type 2 diabetes in people of South Asian origin: Potential strategies for prevention. Br J Diabetes Vasc Dis 2007;7:279–82. 144. Mukhopadhyay B. Diabetes and cardiac disease in South Asians. Br J Diabetes Vasc Dis 2005;5:253–9. 145. UKPDS Study Group. UKPDS 12: Differences between Asian, Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes. UK Prospective Diabetes Study Group. Diabet Med 1994;11:670–7. 146. Nicholl CG, Levy JC, Mohan V, Rao PV, Mather HM. Asian diabetes in Britain: a clinical profile. Diabet Med 1986;3:257–60. 147. Whincup PH, Gilg JA, Owen CG, Odoki K, Alberti KG, Cook DG. British South Asians aged 13–16 years have higher fasting glucose and insulin levels than Europeans. Diabet Med 2005;22:1275–7. 148. Simmons D, Williams DR, Powell MJ. Prevalence of diabetes in a predominantly Asian community: preliminary findings of the Coventry diabetes study. BMJ 1989;298:18–21. 149. Cruickshank JK, Cooper J, Burnett M, MacDuff J, Drubra U. Ethnic differences in fasting plasma C-peptide and insulin in relation to glucose tolerance and blood pressure. Lancet 1991;338:842–7. 150. Simmons D, Williams DR, Powell MJ. Prevalence of diabetes in different regional and religious south Asian communities in Coventry. Diabet Med 1992;9:428–31. 151. Harris TJ, Cook DG, Wicks PD, Cappuccio FP. Impact of the new American Diabetes Association and World Health Organisation diagnostic criteria for diabetes on subjects from three ethnic groups living in the UK. Nutr Metab Cardiovasc Dis 2000;10:305–9. 152. Potts J, Simmons D. Sex and ethnic group differences in fat distribution in young United Kingdom South Asians and Europids. J Clin Epidemiol 1994;47:837–41. 153. Chowdhury TA, Lasker SS. Complications and cardiovascular risk factors in South Asians and Europeans with early-onset type 2 diabetes. QJM 2002;95:241–6. 154. Yajnik CS, Joglekar CV, Lubree HG, Rege SS, Naik SS, Bhat DS, et al. Adiposity, inflammation and hyperglycaemia in rural and urban Indian men: Coronary Risk of Insulin Sensitivity in Indian Subjects (CRISIS) Study. Diabetologia 2008;51:39–46. 155. Samanta A, Burden AC, Jagger C. A comparison of the clinical features and vascular complications of diabetes between migrant Asians and Caucasians in Leicester, UK. Diabetes Res Clin Pract 1991;14:205–13. 156. Chowdhury TA, Lasker SS, Mahfuz R. Ethnic differences in control of cardiovascular risk factors in patients with type 2 diabetes attending an Inner London diabetes clinic. Postgrad Med J 2006;82:211–15. 157. Grace C, Begum R, Subhani S, Kopelman P, Greenhalgh T. Prevention of type 2 diabetes in British Bangladeshis: qualitative study of community, religious, and professional perspectives. BMJ 2008;337:a1931. 158. Ramaiya KL, Denver E, Yudkin JS. Diabetes, impaired glucose tolerance and cardiovascular disease risk factors in the Asian Indian Bhatia community living in Tanzania and in the United Kingdom. Diabet Med 1995;12:904–10. 159. Patel JV, Vyas A, Cruickshank JK, Prabhakaran D, Hughes E, Reddy KS, et al. Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis 2006;185:297–306. 160. Fischbacher CM, Hunt S, Alexander L. How physically active are South Asians in the United Kingdom? A literature review. J Public Health 2004;26:250–8. 161. Carroll R, Ali N, Azam N. Promoting physical activity in South Asian Muslim women through ‘exercise on prescription’. Health Technol Assess 2002;6(8). 162. Bhopal R, Vettini A, Hunt S, Wiebe S, Hanna L, Amos A. Review of prevalence data in, and evaluation of methods for cross cultural adaptation of, UK surveys on tobacco and alcohol in ethnic minority groups. BMJ 2004;328:76. 163. Burden AC. State of the Art Lecture. Rolling stone. The 2007 Arnold Bloom Lecture. Practical Diabetes Int 2007;24:377–83. 164. Knight TM, Smith Z, Whittles A, Sahota P, Lockton JA, Hogg G, et al. Insulin resistance, diabetes, and risk markers for ischaemic heart disease in Asian men and non-Asian in Bradford. Heart 1992;67:343–50. 165. Mukhopadhyay B, Forouhi NG, Fisher BM, Kesson CM, Sattar N. A comparison of glycaemic and metabolic control over time among South Asian and European patients with type 2 diabetes: results from follow-up in a routine diabetes clinic. Diabet Med 2006;23:94–8. 166. Lawton J, Ahmad N, Hanna L, Douglas M, Hallowell N. Diabetes service provision: a qualitative study of the experiences and views of Pakistani and Indian patients with type 2 diabetes. Diabet Med 2006;23:1003–7. 167. Mather HM. Diabetes in elderly Asians. J R Soc Med 1994;87:615–16. 168. Rankin J, Bhopal R. Understanding of heart disease and diabetes in a South Asian community: cross-sectional study testing the ‘snowball’ sample method. Public Health 2001;115:253–60. 169. Mather HM, Chaturvedi N, Fuller JH. Mortality and morbidity from diabetes in South Asians and Europeans: 11-year follow-up of the Southall Diabetes Survey, London, UK. Diabet Med 1998;15:53–9. 170. Mather HM, Chaturvedi N, Kehely AM. Comparison of prevalence and risk factors for microalbuminuria in South Asians and Europeans with type 2 diabetes mellitus. Diabet Med 1998;15:672–7. 171. Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KG, et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ 1999;319:215–20. 172. Oldroyd JC, Yallop J, Fischbacher C, Bhopal R, Chamley J, Ayis S, et al. Transient and persistent impaired glucose tolerance and progression to diabetes in South Asians and Europeans: new, large studies are a priority. Diabet Med 2007;24:98–9. 173. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289–97. 174. Chaturvedi N, Jarrett J, Morrish N, Keen H, Fuller JH. Differences in mortality and morbidity in African Caribbean and European people with non-insulin dependent diabetes mellitus: results of 20 year follow up of a London cohort of a multinational study. BMJ 1996;313:848–52. 175. Odugbesan O, Rowe B, Fletcher J, Walford S, Barnett AH. Diabetes in the UK West indian community: the Wolverhampton survey. Diabet Med 1989;6:48–52. 176. Cooper RS, Rotimi CN, Kaufman JS, Owoaje EE, Fraser H, Forrester T, et al. Prevalence of NIDDM among populations of the African diaspora. Diabetes Care 1997;20:343–8. 177. Mbanya JC, Cruickshank JK, Forrester T, Balkau B, Ngogang JY, Riste L, et al. Standardized comparison of glucose intolerance in west African-origin populations of rural and urban Cameroon, Jamaica, and Caribbean migrants to Britain. Diabetes Care 1999;22:434–40. 178. Centre for Reviews and Dissemination. CRD’s guidance for undertaking reviews in health care. 2008. URL: www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf (accessed 22 March 2012). 179. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007;334:299. 180. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev 2005;2:CD005270. 181. Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Schmid CH, et al. Long-term effectiveness of weight-loss interventions in adults with pre-diabetes: a review. [Erratum published in Am J Prev Med 2005;28:413.] Am J Prev Med 2005;28:126–39. 182. Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a metaanalysis of randomized controlled trials. Diabetes Care 2005;28:2780–6. 183. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–50. 184. Nield L, Summerbell CD, Hooper L, Whittaker V, Moore H. Dietary advice for the prevention of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev 2008;3:CD005102. 185. Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roque IF, Richter B, Mauricio D. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;3:CD003054. 186. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005;67:152–62. 187. Liao D, Asberry PJ, Shofer JB, Callahan H, Matthys C, Boyko EJ, et al. Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. Diabetes Care 2002;25:1504–10. 188. Mensink M, Blaak EE, Corpeleijn E, Saris WH, de Bruin TW, Feskens EJ. Lifestyle intervention according to general recommendations improves glucose tolerance. Obes Res 2003;11:1588–96. 189. Oldroyd JC, Unwin NC, White M, Mathers JC, Alberti KG. Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Res Clin Pract 2006;72:117–27. 190. Pan X-R, Li G-W, Hu Y-H, Wang J-X, Yang W-Y, An Z-X, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and diabetes study. Diabetes Care 1997;20:537–44. 191. Wein P, Beischer N, Harris C, Permezel M. A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance. Aus N Z J Obstet Gynaecol 1999;39:162–6. 192. Diabetes Prevention Program Research Group. Diabetes Prevention Program study documents and website. 2012. URL: www.bsc.gwu.edu/dpp/index.htmlvdoc (accessed 22 March 2012). 193. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006;29:2102–7. 194. Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, Fowler S, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 2006;61:1075–81. 195. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007;24:137–44. 196. Delahanty LM, Conroy MB, Nathan DM, Diabetes Prevention Program Research Group. Psychological predictors of physical activity in the diabetes prevention program. J Am Diet Assoc 2006;106:698–705. 197. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611–19. 198. Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, et al. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes 2007;56:1680–5. 199. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. [Erratum published in Lancet 2009 19;374:2054.] Lancet 2009;374:1677–86. 200. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF, Diabetes Prevention Program Research Group. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 2009;32:1583–8. 201. Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care 2008;31:1416–21. 202. Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009;32:726–32. 203. Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, et al. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 2007;56:1153–9. 204. Ackermann RT, Edelstein SL, Narayan KMV, Zhang P, Engelgau MM, Herman WH, et al. Changes in Health State Utilities With Changes in Body Mass in the Diabetes Prevention Program. Obesity 2009;17:2176–81. 205. Eriksson J, Lindström J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P, et al. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999;42:793–801. 206. Hamalainen H, Ronnemaa T, Virtanen A, Lindström J, Eriksson JG, Valle TT, et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia 2005;48:2248–53. 207. Herder C, Peltonen M, Koenig W, Kraft I, Muller-Scholze S, Martin S, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes 2006;55:2340–6. 208. Ilanne-Parikka P, Eriksson JG, Lindström J, Peltonen M, Aunola S, Hamalainen H, et al. Effect of Lifestyle Intervention on the Occurrence of Metabolic Syndrome and its Components in the Finnish Diabetes Prevention Study. Diabetes Care 2008;31:805–7. 209. Ilanne-Parikka P, Eriksson JG, Lindström J, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, et al. Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care 2004;27:2135–40. 210. Laaksonen DE, Lindström J, Lakka TA, Eriksson JG, Niskanen L, Wikstrom K, et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 2005;54:158–65. 211. Laaksonen DE, Siitonen N, Lindström J, Eriksson JG, Reunanen P, Tuomilehto J, et al. Physical activity, diet, and incident diabetes in relation to an ADRA2B polymorphism. Med Sci Sports Exerc 2007;39:227–32. 212. Lindström J, Peltonen M, Eriksson JG, Aunola S, Hamalainen H, Ilanne-Parikka P, et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care 2008. 213. Lindström J, Peltonen M, Eriksson JG, Louheranta A, Fogelholm M, Uusitupa M, et al. High-fibre, low-fat diet predicts long-term weight loss and decreased type 2 diabetes risk: The Finnish Diabetes Prevention Study. Diabetologia 2006;49:912–20. 214. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673–9. 215. Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230–6. 216. Ottelin AM, Lindström J, Peltonen M, Martikainen J, Uusitupa M, Gylling H, et al. Costs of a self-selected, health-promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care 2007;30:1275–7. 217. Siitonen N, Lindström J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Association between a deletion/insertion polymorphism in the alpha2B-adrenergic receptor gene and insulin secretion and type 2 diabetes. The Finnish Diabetes Prevention Study. Diabetologia 2004;47:1416–24. 218. Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindström J, Tuomilehto J, et al. Longterm improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 2003;52:2532–8. 219. Uusitupa M, Louheranta A, Lindström J, Valle T, Sundvall J, Eriksson J, et al. The Finnish Diabetes Prevention Study. Br J Nutr 2000;83(Suppl. 1):S137–42. 220. Wikstrom K, Peltonen M, Eriksson JG, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, et al. Educational attainment and effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Res Clin Pract 2009;86:e1–5. 221. Lindgren P, Lindström J, Tuomilehto J, Uusitupa M, Peltonen M, Jonsson B, et al. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is costeffective. Int J Technol Assess Health Care 2007;23:177–83. 222. Uusitupa M, Peltonen M, Lindström J, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, et al. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study: secondary analysis of the randomized trial. PLoS ONE 2009;4:e5656. 223. Li G, Hu Y, Yang W, Jiang Y, Wang J, Xiao J, et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study. Diabetes Res Clin Pract 2002;58:193–200. 224. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–9. 225. Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011;54:300–7. 226. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost Effectiveness of the Interventions in the Primary Prevention of Diabetes among Asian Indians: Within trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007;30:2548–52. 227. Ramachandran A. Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians–Result of Indian diabetes prevention programme. Diabetes Res Clin Pract 2007;76:215–18. 228. Ramachandran A, Snehalatha C, Mukesh B, Simon M, Kumar CK, Vijay V. Persistent impaired glucose tolerance has similar rate of risk factors as for diabetes–results of Indian diabetes prevention programme (IDPP). Diabetes Res Clin Pract 2006;73:100–3. 229. Ramachandran A, Arun N, Shetty AS, Snehalatha C. Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2). Diabetes Care 2010;33:2164–8. 230. Snehalatha C, Mary S, Selvam S, Sathish Kumar CK, Shetty SB, Nanditha A, et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). Diabetes Care 2009;32:1796–801. 231. Corpeleijn E, Feskens EJ, Jansen EH, Mensink M, Saris WH, de Bruin TW, et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia 2006;49:2312–409. 232. Corpeleijn E, Feskens EJ, Jansen EH, Mensink M, Saris WH, Blaak EE. Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care 2007;30:3125–7. 233. Mensink M, Corpeleijn E, Feskens EJ, Kruijshoop M, Saris WH, de Bruin TW, et al. Study on lifestyle-intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Res Clin Pract 2003;61:49–58. 234. Mensink M, Feskens EJ, Saris WH, de Bruin TW, Blaak EE. Study on Lifestyle Intervention and Impaired Glucose Tolerance Maastricht (SLIM): preliminary results after one year. Int J Obesity 2003;27:377–84. 235. Roumen C, Corpeleijn E, Feskens EJ, Mensink M, Saris WH, Blaak EE. Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabet Med 2008;25:597–605. 236. Oldroyd JC, Unwin NC, White M, Imrie K, Mathers JC, Alberti KG. Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Res Clin Pract 2001;52:29–43. 237. Penn L, White M, Oldroyd J, Walker M, Alberti KG, Mathers JC. Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health 2009;9:342. 238. Wing RR, Venditti E, Jakicic JM, Polley BA, Lang W. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 1998;21:350–9. 239. Page RC, Harnden KE, Cook JT, Turner RC. Can life-styles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabet Med 1992;9:562–6. 240. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275–83. 241. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36). 242. Caro JJ, Getsios D, Caro I, Klittich WS, O’Brien JA. Economic evaluation of therapeutic interventions to prevent type 2 diabetes in Canada. Diabet Med 2004;21:1229–36. 243. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004;26:304–21. 244. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The costeffectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323–32. 245. Segal L, Dalton AC, Richardson J. Cost-effectiveness of the primary prevention of noninsulin dependent diabetes mellitus. Health Promot Int 1998;13:197–209. 246. McEwan P, Peters JR, Currie CJ. Evaluation of the clinical outcome and financial costs of delaying the onset of frank type 2 diabetes. Diabetes 2005;54:A307. 247. Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P, et al. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care 2006;29:1237–41. 248. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251–64. 249. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003;26:3093–101. 250. Vijgen SMC, Hoogendoorn M, Baan CA, De Wit GA, Limburg W, Feenstra TL. Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review. Pharmacoeconomics 2006;24:425–41. 251. Wylie-Rosett J, Herman WH, Goldberg RB. Lifestyle intervention to prevent diabetes: intensive and cost effective. Curr Opin Lipidol 2006;17:37–44. 252. Eddy DM, Schlessinger L. Validation of the archimedes diabetes model. Diabetes Care 2003;26:3102–10. 253. Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems: the mathematical formulation. J Biomed Inform 2002;35:37–50. 254. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003;26:2518–23. 255. Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KM. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care 2003;26:645–9. 256. Engelgau MM. Trying to predict the future for people with diabetes: a tough but important task. Ann Intern Med 2005;143:301–2. 257. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr. Diabetes 1987;36:523–34. 258. Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner SM, Stern MP. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes 2004;53:160–5. 259. Johnson FR, Clayton LJ, Manjunath R, Hoerger TJ, Mansfield CA, Zhang P. High risk individuals willingness to pay for diabetes risk reduction programs. Diabetes care 2006;29:1351-6. 260. Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM, Baan CA. Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care 2007;30:128–34. 261. Schuit AJ, Wendel-Vos GC, Verschuren WM, Ronckers ET, Ament A, Van AP, et al. Effect of 5-year community intervention Hartslag Limburg on cardiovascular risk factors. Am J Prev Med 2006;30:237–42. 262. Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, et al. Costeffectiveness of screening for pre-diabetes among overweight and obese US adults. Diabetes Care 2007;30:2874–9. 263. Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, et al. Clinical and costeffectiveness of primary prevention of type 2 diabetes in a ‘real world’ routine healthcare setting: model based on the KORA Survey 2000. Diabet Med 2007;24:473–80. 264. Saha S, Gerdtham UG, Johansson P. Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases. Int J Environ Res Public Health 2010;7:3150–95. 265. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008;336:1180–5. 266. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004;8(21). 267. Irvine L, Barton GR, Gasper AV, Murray N, Clark A, Scarpello T, et al. Cost-effectiveness of a lifestyle intervention in preventing type 2 diabetes. Int J Technol Assess Health Care 2011;27:275–82. 268. Ackermann RT, Marrero DG. Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community: the YMCA model. Diabetes Educ 2007;33:69, 74–69, 78. 269. Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia 2010;53:875–81. 270. Colagiuri S, Walker AE. Using an economic model of diabetes to evaluate prevention and care strategies in Australia. Health Affairs 2008;27:256–68. 271. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: UK Prospective Diabetes Study 61. Diabetes Care 2002;25:1410–17. 272. Johansson P, Ostenson CG, Hilding AM, Andersson C, Rehnberg C, Tillgren P. A costeffectiveness analysis of a community-based diabetes prevention program in Sweden. Int J Technol Assess Health Care 2009;25:350–8. 273. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010;33:1872–94. 274. Zhuo X, Zhang P, Gregg EW, Barker L, Hoerger TJ, Pearson-Clarke T, et al. A nationwide community-based lifestyle program could delay or prevent type 2 diabetes cases and save $5.7 billion in 25 years. Health Affairs 2012;31:50–60. 275. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med 2008;35:357–63. 276. General Practice Research Database (GPRD). Observational data representative of the UK population. 2007. URL: www.gprd.com/academia/primarycare.asp (accessed 22 March 2012). 277. Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol 2004;58:303–9. 278. Wood SL, Jick H, Sauve R. The risk of stillbirth in pregnancies before and after the onset of diabetes. Diabet Med 2003;20:703–7. 279. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002;63:758–62. 280. Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999;22:2067–71. 281. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a nondiabetic population from the UK general practice research database, 1992–1999. Diabetologia 2006;49:660–6. 282. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA. Mortality in people with type 2 diabetes in the UK. Diabet Med 2006;23:516–21. 283. Gulliford MC, Charlton J, Latinovic R. Increased utilization of primary care 5 years before diagnosis of type 2 diabetes: a matched cohort study. Diabetes Care 2005;28:47–52. 284. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686–9. 285. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735–44. 286. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776–81. 287. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 2001;101:671–9. 288. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004;27:201–7. 289. Tan HH, McAlpine RR, James P, Thompson P, McMurdo ME, Morris AD, et al. Diagnosis of type 2 diabetes at an older age: effect on mortality in men and women. Diabetes Care 2004;27:2797–9. 290. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and nutrition (EPIC-Norfolk). BMJ 2001;322:15–18. 291. Woerle HJ, Pimenta WP, Meyer C, Gosmanov NR, Szoke E, Szombathy T, et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. Arch Intern Med 2004;164:1627–32. 292. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care 2001;24:447–53. 293. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–97. 294. Valensi P, Schwarz EH, Hall M, Felton AM, Maldonato A, Mathieu C. Pre-diabetes essential action: a European perspective. Diabetes Metab 2005;31:606–20. 295. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001;285:2109–13. 296. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753–9. 297. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess 2001;5(32). 298. Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 2006;29:1997–2002. 299. Swinburn BA, Metcalf PA, Ley SJ. Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care 2001;24:619–24. 300. Curtis L. Unit costs of health and social care. 2007. URL: www.pssru.ac.uk/project-pages/unitcosts/ 2007/index.php (accessed 22 March 2012). 301. On-line currency conversion. 2008. URL: http://currencyconverter.uk.com/ (accessed 22 March 2012). 302. Nichols G. Preventing and predicting diabetes. Medscape report on 2007 American Diabetes Association (ADA) 67th Scientific Sessions. 2007. URL: www.medscape.com/ viewarticle/560724_2 (accessed 22 March 2012). 303. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med 2007;24:451–63. 304. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 54, September 2007. URL: www.bnf.org/bnf/ (accessed 22 March 2012). 305. Kopjar B, Sales AE, Pineros SL, Sun H, Li YF, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol 2003;92:1106–8. 306. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423. 307. Ward S, Lloyd JM, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11(14). 308. Costa J, Borges M, David C, Vaz CA. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332:1115–24. 309. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154–9. 310. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–43. 311. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217–30. 312. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238–43. 313. Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 2004;24:9–19. 314. O’Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. The clinical effectiveness and costeffectiveness of sibutramine in the management of obesity: a technology assessment. Health Technol Assess 2002;6(6). 315. Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health 2008;11:478–86. 316. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 2008;371:736–43. 317. Quality framework at GPcontract.info. National Quality and Outcomes Framework incorporated into 2004 GP contract. 2004. URL: www.gpcontract.info/quality/qualitydiabetes. htm (accessed 22 March 2012). 318. Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007;24:1412–18.
URI:	http://wrap.warwick.ac.uk/id/eprint/52117

Request changes to a record

Actions (login required)

View Item